Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
$45.66
-$2.14(-2.45%)
At close: 4:00 PM EST
$45.66
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$27.66 - $100.68
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.68M
Market Cap
$5.62B
Enterprise Value$3.28B
Total Cash (Recent Filing)$1.71B
Total Debt (Recent Filing)$84.44M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 02, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding130,906,270
10 Day Avg. Volume1,369,793
30 Day Avg. Volume1,677,599
Financial Highlights & Ratios
PEG Ratio2.62
Price to Book (P/B)3.02
Price to Sales (P/S)0.00
P/FCF Ratio-21.02
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-657.23
Enterprise Value/Ebitda-5.47
Forecast
1Y Price Target
$90.33Price Target Upside97.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityPCVX ended the quarter with $2.7B in cash and investments, which is expected to provide runway to 2028.
Strategic AdvantageVAX-31 in children only needs to be better than PCV20, which provides a strategic advantage.
ValuationPCVX is undervalued based on the promising 2026 VAX-31 Phase III data alone.
Bears Say
Efficacy In ChildrenThe results from VAX-24 in children were materially less impressive than those for adults.
Non-Inferiority ConcernsVAX-31 will fail to be non-inferior to PCV20 for 2-4 serotypes, although it provides similar protection to 75% of children.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $100.68 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $5.62B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 109 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Nov 04, 2025. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.238 by -$0.322.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.46.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 130,906,270 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.238. Following the earnings report the stock price went down -2.491%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
Vaxcyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.33 (97.83% Upside)
$90.33 (97.83% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.94%
12-Months-Change
Fundamentals
Return on Equity
-20.83%
Trailing 12-Months
Asset Growth
-10.90%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$90.33
▲(97.83% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
41.12% Mutual Funds
0.20% Other Institutional Investors
41.15% Public Companies and Individual Investors